Highlighting the development of a new in vivo immune cell engineering modality for cancer immunotherapy, delivering differentiated therapeutic potential

Designing first-in-human clinical trial strategies for this novel approach, accelerating proof-of-concept while ensuring patient safety

Outlining future pipeline ambitions and long-term goals, driving sustained innovation and clinical impact